TIDMABDX
Abingdon Health PLC
05 April 2022
Abingdon Health plc
("Abingdon" or "the Company")
Completion of Technical Transfer to full-scale manufacture and
initial orders for Vatic KnowNow(TM) test
Tests manufactured by Abingdon now authorised for sale
York, U.K. 5 April 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, announces it has successfully completed
the technical transfer of the Vatic KnowNow test (Spike Test in
USA) on behalf of its customer, leading diagnostics technology
innovator Vatic Health Limited ("Vatic"), on schedule. This follows
the conclusion of the scale-up and manufacture of three independent
production-scale batches and Vatic has now approved the sale of
tests manufactured by Abingdon. Abingdon has received initial
purchase orders from Vatic for commercial sale, and manufacturing
for these orders will now commence.
The Vatic KnowNow test is an easy-to-use saliva COVID-19 antigen
test, which is the only test that identifies the virus by mimicking
the surface of a human cell. This means the test only identifies
"live" or "active" copies of the virus which are capable of cell
entry and thereby infecting a human cell. Other tests, such as PCR
and lateral flow antigen tests, can pick up harmless viral
fragments with the potential for users to test positive once they
are no longer infectious. Furthermore, the unique detection
mechanism of the KnowNow test has been purposefully designed to be
more robust to mutation than traditional antigen tests, making it
more future-proofed for ongoing COVID-19 testing. Vatic have
previously announced that this test detects variants of the
SARS-CoV-2 virus including the Omicron variant.
The test is CE marked for professional use and has been
submitted by Vatic to the US FDA for Emergency Use Approval
(EUA).
Alex Sheppard, CEO of Vatic Health Limited, commented:
"We are excited to have concluded the transfer of our product to
manufacture with Abingdon and to commence sales of our product. Our
proprietary technology allows ease of use via a saliva specimen and
only detects active virus -enabling individuals to know their
infectivity status."
Dr Mona K. Omir, CTO of Vatic Health Limited, commented:
"Completing the Technical Transfer of the KnowNow test is a huge
milestone in the Vatic Health journey and our ongoing collaboration
with Abingdon Health. To bring such novel assay technology into
routine manufacturing could be a true step change in diagnostics
and we are excited for what this could mean for COVID-19 testing
around the world."
Chris Yates, CEO of Abingdon Health plc, commented:
"We are delighted to have concluded this technical transfer and
to begin manufacture of the product for Vatic at our Yorkshire
facilities. This is an important addition to the COVID-19 testing
toolbox and we look forward to continuing to work with Vatic as we
manufacture the product to fulfil their requirements."
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross, Chief Financial Officer
Dr Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Marriage 082
Alice Woodings Mob: +44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
About Vatic Health
Vatic Health is an Innovate UK and VC backed start-up, supported
by the University of Oxford and the Oxford Foundry. They are a team
of scientists, engineers and designers solving the world's most
critical healthcare problems with a focus on the inequality of
access to health data.
Vatic's vision is a world in which everyone has access to
proactive diagnostic tools in the community and at home. This means
the rapid tools to help people know about acute illness before it
happens, and a way to assess this data and turn it into
personalised, actionable insights that provide real benefits to
real people.
They take a unique approach to lateral flow immunoassays, taking
inspiration from nature to create novel rapid tests with
dramatically increased sensitivity of detection, unlike traditional
approaches. The first deployment of this proprietary technology is
in its COVID-19 test (KnowNow(TM), EU and Spike Test, USA).
Founded in 2019, Vatic Health is headquartered in London,
England.
For more information visit: www.vatic.health
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASLLEDLAEFA
(END) Dow Jones Newswires
April 05, 2022 02:01 ET (06:01 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
